BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 30324220)

  • 21. Pharmacogenomics of intracellular methotrexate polyglutamates in patients' leukemia cells in vivo.
    Lopez-Lopez E; Autry RJ; Smith C; Yang W; Paugh SW; Panetta JC; Crews KR; Bonten EJ; Smart B; Pei D; McCorkle JR; Diouf B; Roberts KG; Shi L; Pounds S; Cheng C; Mullighan CG; Pui CH; Relling MV; Evans WE
    J Clin Invest; 2020 Dec; 130(12):6600-6615. PubMed ID: 33164984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Methotrexate intracellular disposition in acute lymphoblastic leukemia: a mathematical model of gamma-glutamyl hydrolase activity.
    Panetta JC; Wall A; Pui CH; Relling MV; Evans WE
    Clin Cancer Res; 2002 Jul; 8(7):2423-9. PubMed ID: 12114448
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measures of 6-mercaptopurine and methotrexate maintenance therapy intensity in childhood acute lymphoblastic leukemia.
    Nielsen SN; Grell K; Nersting J; Frandsen TL; Hjalgrim LL; Schmiegelow K
    Cancer Chemother Pharmacol; 2016 Nov; 78(5):983-994. PubMed ID: 27600880
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO).
    Schmiegelow K; Glomstein A; Kristinsson J; Salmi T; Schrøder H; Björk O
    J Pediatr Hematol Oncol; 1997; 19(2):102-9. PubMed ID: 9149738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Shortening infusion time for high-dose methotrexate alters antileukemic effects: a randomized prospective clinical trial.
    Mikkelsen TS; Sparreboom A; Cheng C; Zhou Y; Boyett JM; Raimondi SC; Panetta JC; Bowman WP; Sandlund JT; Pui CH; Relling MV; Evans WE
    J Clin Oncol; 2011 May; 29(13):1771-8. PubMed ID: 21444869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Transition of Methotrexate Polyglutamate Drug Monitoring Assay from Venipuncture to Capillary Blood-Based Collection Method in Rheumatic Diseases.
    Brady K; Qu Y; Stimson D; Apilado R; Vezza Alexander R; Reddy S; Chitkara P; Conklin J; O'Malley T; Ibarra C; Dervieux T
    J Appl Lab Med; 2019 Jul; 4(1):40-49. PubMed ID: 31639706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling mechanisms of in vivo variability in methotrexate accumulation and folate pathway inhibition in acute lymphoblastic leukemia cells.
    Panetta JC; Sparreboom A; Pui CH; Relling MV; Evans WE
    PLoS Comput Biol; 2010 Dec; 6(12):e1001019. PubMed ID: 21152005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of high-dose methotrexate on intracellular 6-mercaptopurine disposition during interval therapy of childhood acute lymphoblastic leukemia.
    Adam de Beaumais T; Dervieux T; Fakhoury M; Medard Y; Azougagh S; Zhang D; Yakouben K; Jacqz-Aigrain E
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):653-8. PubMed ID: 20033410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia.
    Schmiegelow K; Björk O; Glomstein A; Gustafsson G; Keiding N; Kristinsson J; Mäkipernaa A; Rosthøj S; Szumlanski C; Sørensen TM; Weinshilboum R
    J Clin Oncol; 2003 Apr; 21(7):1332-9. PubMed ID: 12663723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of TPMT and ITPA variants in mercaptopurine disposition.
    Gerbek T; Ebbesen M; Nersting J; Frandsen TL; Appell ML; Schmiegelow K
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):579-586. PubMed ID: 29387964
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay.
    Rots MG; Pieters R; Kaspers GJ; van Zantwijk CH; Noordhuis P; Mauritz R; Veerman AJ; Jansen G; Peters GJ
    Blood; 1999 Feb; 93(3):1067-74. PubMed ID: 9920857
    [TBL] [Abstract][Full Text] [Related]  

  • 32. gamma-Glutamyl hydrolase and folylpolyglutamate synthetase activities predict polyglutamylation of methotrexate in acute leukemias.
    Longo GS; Gorlick R; Tong WP; Lin S; Steinherz P; Bertino JR
    Oncol Res; 1997; 9(5):259-63. PubMed ID: 9306433
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA incorporation of 6-thioguanine nucleotides during maintenance therapy of childhood acute lymphoblastic leukaemia and non-Hodgkin lymphoma.
    Hedeland RL; Hvidt K; Nersting J; Rosthøj S; Dalhoff K; Lausen B; Schmiegelow K
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):485-91. PubMed ID: 19956952
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differences in folylpolyglutamate synthetase and dihydrofolate reductase expression in human B-lineage versus T-lineage leukemic lymphoblasts: mechanisms for lineage differences in methotrexate polyglutamylation and cytotoxicity.
    Galpin AJ; Schuetz JD; Masson E; Yanishevski Y; Synold TW; Barredo JC; Pui CH; Relling MV; Evans WE
    Mol Pharmacol; 1997 Jul; 52(1):155-63. PubMed ID: 9224825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of common polymorphisms in reduced folate carrier and gamma-glutamylhydrolase to methotrexate polyglutamate levels in patients with rheumatoid arthritis.
    Dervieux T; Kremer J; Lein DO; Capps R; Barham R; Meyer G; Smith K; Caldwell J; Furst DE
    Pharmacogenetics; 2004 Nov; 14(11):733-9. PubMed ID: 15564880
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia.
    Vang SI; Schmiegelow K; Frandsen T; Rosthøj S; Nersting J
    Cancer Chemother Pharmacol; 2015 May; 75(5):1089-93. PubMed ID: 25788208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence for negative feedback of extracellular methotrexate on blasts of acute lymphoblastic leukemia in vitro.
    Hum MC; Smith AK; Lark RH; Winick NJ; Kamen BA
    Pharmacotherapy; 1997; 17(6):1260-6. PubMed ID: 9399609
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Basis for natural resistance to methotrexate in human acute non-lymphocytic leukemia.
    Lin JT; Tong WP; Trippett TM; Niedzwiecki D; Tao Y; Tan C; Steinherz P; Schweitzer BI; Bertino JR
    Leuk Res; 1991; 15(12):1191-6. PubMed ID: 1722550
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of germline DHFR and FPGS variants on methotrexate metabolism and relapse of leukemia.
    Tulstrup M; Moriyama T; Jiang C; Grosjean M; Nersting J; Abrahamsson J; Grell K; Hjalgrim LL; Jónsson ÓG; Kanerva J; Lund B; Nielsen SN; Nielsen RL; Overgaard U; Quist-Paulsen P; Pruunsild K; Vaitkeviciene G; Wolthers BO; Zhang H; Gupta R; Yang JJ; Schmiegelow K
    Blood; 2020 Sep; 136(10):1161-1168. PubMed ID: 32391884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia.
    French D; Yang W; Cheng C; Raimondi SC; Mullighan CG; Downing JR; Evans WE; Pui CH; Relling MV
    Blood; 2009 May; 113(19):4512-20. PubMed ID: 19066393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.